Smith Mark Douglas sold $267K of JAZZ
Smith Mark Douglas sold 1,157 shares of Jazz Pharmaceuticals plc (JAZZ) at $230.55 ($0.27M total) on 2026-06-15 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The only new information is the disclosed sale size, price ($230.55/share), and that it was executed under a pre-arranged 10b5-1 plan.
Market read
Traders may note the insider sale, but the 10b5-1 designation and lack of fundamental updates make it a low-conviction signal.
What to watch
The article does not state total position size changes beyond the post-transaction holdings, nor whether other insiders sold or bought around the same period.
Background
The article is a SEC Form 4 insider transaction disclosure for Jazz Pharmaceuticals plc, reported by a director.
Ticker impact
Jazz Pharmaceuticals director Mark Douglas sold 1,157 shares in an open-market transaction for about $266,746, under a 10b5-1 plan.
Likely limited near-term impact; treat as low-signal unless paired with other negative company-specific news.
The filing is a Form 4 insider sale, explicitly tied to a pre-arranged 10b5-1 plan, and the article provides no new guidance, trial, deal, or regulatory development.
Market effects
No clear sector read-through; this is company-specific insider activity without additional disclosures.
None indicated.
None indicated.
Counterpoint
Even with a 10b5-1 plan, repeated or unusually large insider sales can sometimes coincide with private concerns; monitor for follow-on filings.
Key entities
- issuerJazz Pharmaceuticals plc
Subject of the Form 4 insider sale disclosure.
- insiderMark Douglas Smith
Director who sold 1,157 shares in an open-market transaction under a 10b5-1 plan.
